Galmed Pharma Revenue, Profits - GLMD Annual Income Statement

Add to My Stocks
$12.83 $0.04 (0.31%) GLMD stock closing price Sep 20, 2018 (Closing)

Looking at financial statements, along with the Galmed Pharma stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue increase to $1.08M for 2017 impacts the GLMD stock. Investors typically check year over year or quarter over quarter revenue growth. The Galmed Pharma profit and loss statement for 2017 shows a net profit of $-12.29M. Profits for last year was $-16.95M. Apart from this an investor should also check Galmed Pharma assets and Galmed Pharma free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec201720162015201420132012
Galmed Pharma Revenues or Net Sales
1.08M-----
Cost Of Goods Sold (COGS)------
Galmed Pharma Gross Profit
1.08M-----
Research & Development Expense9.65M14.27M7.62M6.66M7.2M2.44M
Selling General & Admin Expense3.79M3.07M3.24M2.47M7.36M-
Income Before Depreciation Depletion Amortization-12.36M-16.88M-10.87M-9.14M-14.57M-3.13M
Depreciation Depletion Amortization------
Non Operating Income----0.04M-2.91M-0.01M
Interest Expense------
Galmed Pharma Pretax Income
-12.29M-16.84M-10.62M9.1M-17.48M3.14M
Provision for Income Taxes------
MinorityInterest------
Investment Gains Losses------
Other Income------
Income Before Extraordinaries & Disc Operations-12.29M-16.95M-10.62M9.1M-17.48M3.13M
Extraordinary Items & Discontinued Operations------
Galmed Pharma Profit/ Loss (Net Income)
-12.29M-16.95M-10.62M9.1M-17.48M3.13M
Average Shares used to compute Diluted EPS12.49M11.38M11.1M10.32M5.07M5M
Average Shares used to compute Basic EPS12.49M11.38M11.1M10.32M5.07M5M
Income Before Nonrecurring Items-12.3M-16.95M-10.62M-9.1M17.49M3.15M
Income from Nonrecurring Items------
Galmed Pharma Earnings Per Share Basic Net
-0.98-1.49-0.96-0.883.450.63
Galmed Pharma Earnings Per Share Diluted Net
-0.98-1.49-0.96-0.883.450.63
EPS Diluted Before Nonrecurring Items-0.98-1.49-0.96-0.883.450.63
Preferred Dividends Acc Pd------
Dividends Common------
Dividend Per Share Common0.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

The key things to look for in an income statement while doing Galmed Pharma stock analysis are:

  • Topline: A growing topline, as seen from the Galmed Pharma revenue chart, as is the case with Galmed Pharma indicates a growing business. One needs to compare the YoY topline or sales growth of GLMD stock with its peers like JNCE stock and GALT stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-12.29M for GLMD stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the GLMD income statement, one can check the Galmed Pharma historical stock prices to check how the price has moved with time.

Galmed Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
186.63
Dividend Yield
0%